Who is sponsoring NCT04979195?

NCT04979195 is sponsored by Hamid Al-Essa Organ Transplant Center.

What drugs are being tested in NCT04979195?

Interventions in NCT04979195: Patients with stable normal kidney function, Patients with unstable kidney function.

What condition does NCT04979195 study?

NCT04979195 studies COVID-19 Positive Patients With Acute Kidney Injury.

Is NCT04979195 still recruiting?

NCT04979195 is currently completed. Last updated 28 July 2021.

Last reviewed 2021-07-28 · How we verify

NCT04979195: AKI-COVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute Kidney Injury Among COVID-19 Positive Patients

Completed Last updated 28 July 2021

What this trial tests

trial testing Patients with stable normal kidney function in COVID-19 Positive Patients With Acute Kidney Injury in 649 participants. Completed in 31 August 2020.

Timeline

1 March 2020

Primary endpoint
31 August 2020

31 August 2020

Quick facts

Lead sponsor	Hamid Al-Essa Organ Transplant Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	649
Start date	1 March 2020
Primary completion	31 August 2020
Estimated completion	31 August 2020
Sites	2 locations across Kuwait

Drugs / interventions tested

Patients with stable normal kidney function
Patients with unstable kidney function

Conditions studied

COVID-19 Positive Patients With Acute Kidney Injury — all drugs for COVID-19 Positive Patients With Acute Kidney Injury →

Sponsor

Hamid Al-Essa Organ Transplant Center

Who can join

Adults 21 to 90, any sex, with COVID-19 Positive Patients With Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In Kuwait, the total number of COVID-19 confirmed cases exceeds 5000 patients. Risk factors of possible risk factors of confirmed COVID-19 infection that developed major organ dysfunction are not yet identified among patients in Kuwait. we aimed to describe the clinical characteristics of hospitalized symptomatic COVID-19 positive patients, assess possible risk factors of confirmed COVID-19 infection who developed major organ dysfunction, determine risk factors for renal dysfunction and their outcome and assess the response of critically ill patients to different therapeutic modalities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Hamid Al-Essa Organ Transplant Center trials

Trials by the same sponsor.

NCT04542954 — Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East · completed
NCT04665830 — PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients · Phase 3 · completed
NCT03861637 — Impact of Full Correction of PTA in Renal Transplant Recipients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04979195 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hamid Al-Essa Organ Transplant Center
Last refreshed: 28 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04979195.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing